Chih-Ming Tseng

Title: Chih-Ming Tseng: Innovator in Therapeutic Peptide Conjugates

Introduction

Chih-Ming Tseng is a notable inventor based in Herzliya, Israel. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic regimens for treating nonalcoholic steatohepatitis. His innovative work has led to the filing of multiple patents that showcase his expertise and dedication to advancing medical treatments.

Latest Patents

Chih-Ming Tseng holds 2 patents related to methods of treatment using mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates. His latest patents focus on therapeutic regimens that utilize these conjugates, which comprise a polyethylene glycol (PEG) moiety attached to a mutant FGF-21 peptide via a glycosyl moiety. These innovative methods aim to provide effective treatments for nonalcoholic steatohepatitis, highlighting the potential of peptide conjugates in modern medicine.

Career Highlights

Chih-Ming Tseng is currently associated with 89Bio, Inc., where he continues to push the boundaries of therapeutic innovation. His work at the company emphasizes the importance of research and development in creating effective treatments for complex health issues. His contributions have been instrumental in advancing the understanding and application of peptide conjugates in therapeutic settings.

Collaborations

Chih-Ming Tseng collaborates with Hank Mansbach, further enhancing the innovative efforts at 89Bio, Inc. Their partnership exemplifies the collaborative spirit that drives progress in the field of biotechnology.

Conclusion

Chih-Ming Tseng's work in developing therapeutic peptide conjugates represents a significant advancement in the treatment of nonalcoholic steatohepatitis. His patents and ongoing research contribute to the evolving landscape of medical therapies, showcasing the impact of innovation in healthcare.